Why do you report EtG levels at two different cut-offs 100 ng\/ml, 250mg\/ml and 500 ng\/ml?<\/strong><\/p>\n\n\n\nWe do this to provide complete information on which to base a sound clinical decision. EtG can be detected by our assay system at levels even below 100 ng\/ml, but we build in a \u201cmargin of safety\u201d so that at 100 ng\/ml we are very certain that EtG is present, indicating even small amounts of drinking. However, there have been some reports in the literature, as well as concern raised in legal cases, that other sources of alcohol (e.g. mouthwash, hand sanitizer) might cause levels of EtG above 100 ng\/ml to be detected in the urine. Although these situations are rare, and hard to replicate under controlled conditions, in those instances where a higher level of certainty is needed (forensic cases etc.) the clinician might want to use the 250 or 500 ng\/ml cut-off.<\/p>\n\n\n\n
EtG alcohol testing should not be used for standard workplace alcohol testing<\/strong>. The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued an advisor warning: The EtG (ethyl glucuronide) urine test, often used to detect alcohol use among individuals legally prohibited from drinking because of their job or parole status, is “inappropriate” as the sole basis for a definitive, life-altering decision. SAMHSA issued the warning after investigating claims of false-positive test results.<\/p>\n\n\n\nThe EtG test and other similar highly sensitive tests are not able to distinguish between alcohol absorbed into the body from exposure to many common commercial and household products containing alcohol or from the actual consumption of alcohol. Calling such a test “positive” for consumption or relapse, especially at low concentrations, could have devastating consequences for someone who signs an alcohol abstinence contract or is required to be abstinent by law.<\/p>\n\n\n\n
“This Advisory is a clarification,” said addiction psychiatrist Kenneth Hoffman, M.D., M.P.H., of SAMHSA’s Center for Substance Abuse Treatment Division of Pharmacologic Therapies. “The Agency wants officials to know that the EtG test, for example, is fine for use in clinical settings. But it should not be used as a stand-alone test in a forensic situation where someone’s job is at stake.”<\/p>\n\n\n\n
National Drug Screening agrees with SAMHSA and does not provide EtG testing for employer based drug testing programs and drug free workplace problems. For workplace alcohol testing should be done with breath alcohol testing or with blood alcohol testing.<\/p>\n","protected":false},"excerpt":{"rendered":"
… EtG and EtS are direct metabolites of alcohol (ethanol). Their presence in urine is used to detect recent ethanol ingestion\u2014even after ethanol is no longer measurable. Detectable up to 80 hours after ingestion, the presence of both EtG and EtS in urine is a reliable confirmation method and indicator of ethanol ingestion.\u00a0 EtG detects […]<\/p>\n","protected":false},"author":12,"featured_media":51751,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"51535,51391,51395,51158,51229,50935","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/50878"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=50878"}],"version-history":[{"count":0,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/50878\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/51751"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=50878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=50878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=50878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}